


Accepted Manuscript

Riociguat: Mode of action and clinical development in pulmonary hypertension

Hosseini-Ardeschir Ghofrani, MD, Marc Humbert, MD, David Langleben, MD, Ralph Schermuly, MD, Johannes-Peter Stasch, PhD, Martin R. Wilkins, MD, James R. Klinger, MD



PII: S0012-3692(16)49111-7

DOI: [10.1016/j.chest.2016.05.024](https://doi.org/10.1016/j.chest.2016.05.024)

Reference: CHEST 493

To appear in: *CHEST*

Received Date: 18 November 2015

Revised Date: 5 April 2016

Accepted Date: 24 May 2016

Please cite this article as: Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR, Riociguat: Mode of action and clinical development in pulmonary hypertension, *CHEST* (2016), doi: 10.1016/j.chest.2016.05.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Riociguat MoA for clinicians review: Final draft

WORD COUNT: ABSTRACT: 133 [MAX 250] TEXT: 3913 [MAX 3500]

Riociguat: Mode of action and clinical development in pulmonary hypertension

Hossein-Ardeschir Ghofrani, MD; Marc Humbert, MD; David Langleben, MD; Ralph Schermuly, MD; Johannes-Peter Stasch, PhD; Martin R. Wilkins, MD; and James R. Klinger, MD

AFFILIATIONS: From the University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center for Lung Research (DZL) (Drs Ghofrani and Schermuly), Department of Medicine, Imperial College London, London, UK (Drs Ghofrani and Wilkins), Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre and Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique and INSERM Unité 999, Le Kremlin–Bicêtre, France (Dr Humbert), Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada (Dr Langleben), Bayer Pharma AG, Wuppertal and University Halle, Institute of Pharmacy, Halle (Saale), Germany (Dr Stasch), Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI (Dr Klinger).

CORRESPONDENCE TO: Hossein-Ardeschir Ghofrani, MD, Department of Internal Medicine, Medical Clinic II/V, University Hospital Giessen and Marburg, Klinikstr.33, Giessen 35392, Germany. e-mail: ardeschir.ghofrani@innere.med.uni-giessen.de

Funding/Support:

Editorial assistance was provided by Adelphi Communications Ltd (Bollington, UK), supported by Bayer Pharma AG (Berlin, Germany).

Financial/nonfinancial disclosures:

Download English Version:

<https://daneshyari.com/en/article/5600410>

Download Persian Version:

<https://daneshyari.com/article/5600410>

[Daneshyari.com](https://daneshyari.com)